1. A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies.
- Author
-
Bisht S, Schlesinger M, Rupp A, Schubert R, Nolting J, Wenzel J, Holdenrieder S, Brossart P, Bendas G, and Feldmann G
- Subjects
- Animals, Antineoplastic Agents chemistry, Antineoplastic Agents pharmacokinetics, Benzylidene Compounds chemistry, Benzylidene Compounds pharmacokinetics, Cell Line, Tumor, Cell Survival drug effects, Deoxycytidine chemistry, Deoxycytidine pharmacokinetics, Deoxycytidine pharmacology, Disease Progression, Drug Compounding, Drug Therapy, Combination, Humans, I-kappa B Kinase genetics, I-kappa B Kinase metabolism, Injections, Subcutaneous, Liposomes chemistry, Mice, NF-kappa B antagonists & inhibitors, NF-kappa B genetics, NF-kappa B metabolism, Pancreatic Neoplasms genetics, Pancreatic Neoplasms metabolism, Pancreatic Neoplasms pathology, Phosphorylation drug effects, Piperidones chemistry, Piperidones pharmacokinetics, Signal Transduction, Xenograft Model Antitumor Assays, Gemcitabine, Antineoplastic Agents pharmacology, Benzylidene Compounds pharmacology, Deoxycytidine analogs & derivatives, Gene Expression Regulation, Neoplastic, Liposomes administration & dosage, Pancreatic Neoplasms drug therapy, Piperidones pharmacology
- Abstract
Background: Pancreatic cancer is one of the most lethal of human malignancies known to date and shows relative insensitivity towards most of the clinically available therapy regimens. 3,5-bis(2-fluorobenzylidene)-4-piperidone (EF24), a novel synthetic curcumin analog, has shown promising in vitro therapeutic efficacy in various human cancer cells, but insufficient water solubility and systemic bioavailability limit its clinical application. Here, we describe nano-encapsulation of EF24 into pegylated liposomes (Lipo-EF24) and evaluation of these particles in preclinical in vitro and in vivo model systems of pancreatic cancer., Results: Transmission electron microscopy and size distribution studies by dynamic light scattering confirmed intact spherical morphology of the formed liposomes with an average diameter of less than 150 nm. In vitro, treatment with Lipo-EF24 induced growth inhibition and apoptosis in MIAPaCa and Pa03C pancreatic cancer cells as assessed by using cell viability and proliferation assays, replating and soft agar clonogenicity assays as well as western blot analyses. Lipo-EF24 potently suppressed NF-kappaB nuclear translocation by inhibiting phosphorylation and subsequent degradation of its inhibitor I-kappa-B-alpha. In vivo, synergistic tumor growth inhibition was observed in MIAPaCa xenografts when Lipo-EF24 was given in combination with the standard-of-care cytotoxic agent gemcitabine. In line with in vitro observations, western blot analysis revealed decreased phosphorylation of I-kappa-B-alpha in excised Lipo-EF24-treated xenograft tumor tissues., Conclusion: Due to its promising therapeutic efficacy and favorable toxicity profile Lipo-EF24 might be a promising starting point for development of future combinatorial therapeutic regimens against pancreatic cancer.
- Published
- 2016
- Full Text
- View/download PDF